Corvus Aims To Master Adenosine Mechanisms For PD-1/L1 Failures

Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.